Hints and tips:
Related Special Reports
...The US drugmaker has spent almost $30bn on acquisitions over the past two years, snapping up Arena Pharmaceuticals, Biohaven Pharmaceuticals, Global Blood Therapeutics, ReViral and Trillium Therapeutics....
...“The next test case many of us are watching is Pfizer’s acquisition of Arena Pharmaceuticals,” says Loncar....
...There were several massive deals in 2009, including Pfizer’s purchase of Wyeth; Merck’s of Schering-Plough; and Roche’s of Genentech....
...Investors say Pfizer is in much better shape than when he took the top job in 2010, shortly after the company had completed the ill-fated acquisition of Wyeth for $68bn....
...The current version, mostly acquired with Wyeth in 2009, includes brands such as Centrum supplements and ChapStick....
...But it subsequently took on a new portfolio when it acquired Wyeth in 2010....
...Analysts have suggested that Pfizer might use the proceeds from any sale to help fund a large deal in the pharmaceuticals sector....
...its consumer division to J&J for $16.6bn in 2006, parting ways with brands such as Listerine mouthwash and Nicorette anti-smoking treatments, but it subsequently took on a new portfolio when it acquired Wyeth...
...A Louisiana doctor who has brought a series of whistleblower lawsuits against pharmaceuticals companies is in line for a windfall from Pfizer that would take his total payout from fraud settlements close...
...Martoma had obtained non-public information about an experimental drug for Alzheimer’s that was being developed by listed companies Elan and Wyeth....
...Before Pfizer bought Wyeth in 2009, the two companies employed 124,000 people. Pfizer now employs 78,000. Mr Read is quite right about maximising returns over the long run, though....
...In 2009, Pfizer paid $68bn to buy Wyeth. The buyer had revenues of $48bn; the target, $23bn....
...When Pfizer revealed its most recent mega-merger, the $68bn takeover of Wyeth in 2009, Jeffrey Kindler, then chief executive, hailed the deal as “a powerful opportunity to transform our industry”....
...The marriage between the makers of Viagra and Botox would, if consummated, create the world’s biggest pharmaceuticals group....
...for $90bn in 2000 and Wyeth for $68bn in 2009, were formed....
...“You do need critical mass in [core] therapeutic areas . . . but just being an enormous pharmaceuticals company is not the criteria.”...
...A similar case could have been made for John and Frank Wyeth, the Philadelphia pharmacists who built one of America’s earliest pharmaceuticals giants on the back of supplying medicines to the Union army...
...Since the start of last year, pharmaceuticals companies have agreed $462bn of mergers and acquisitions — greater than the gross domestic product of Austria....
...which was the most frequently purchased vitamin and supplement brand in China Confidential’s survey (see chart), and Pfizer’s Centrum brand, which was introduced to China 18 years ago by previous owners Wyeth...
...At the heart of debate over the future of AstraZeneca is a simple question: In whose hands would the pharmaceutical company’s laboratories produce the most valuable drugs?...
...Its last big deal, $68bn for Wyeth in 2009, began with $4bn in promised savings. After a merger, R&D can be held back by fear – of projects being cancelled or of staff being made redundant....
...Some analysts have expressed puzzlement over Pfizer’s move, which seems at odds with Mr Read’s efforts in recent years to slim down the group after a series of megadeals such as its $69bn takeover of Wyeth...
...The writer is the FT’s pharmaceuticals correspondent...
...AstraZeneca is not only important to Britain’s future as a leader in the pharmaceuticals industry....
...Yet the prospect of an activist-backed offer from Valeant Pharmaceuticals for Allergan and speculation over a potential $100bn bid by Pfizer for AstraZeneca suggests it may have been too soon to call an...
International Edition